[SCHEDULE 13G] BioCardia, Inc. SEC Filing

Rhea-AI Filing Summary

BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.

Positive

• Clear disclosure of beneficial ownership totaling 557,179 shares (4.99%)
• Blocker provisions in warrants that prevent inadvertent crossing of the 4.99% ownership threshold
• Joint filing and certification stating holdings were not acquired to influence control

Negative

• Potential dilution exists from additional warrants and shares referenced, although exercise is restricted by blockers
• Material details missing: the filing references a Securities Purchase Agreement and SPA closing issuances but does not disclose economic terms or pricing in this Schedule 13G

Insights

Financial Analyst

TL;DR: Reporting persons hold 4.99% via warrants and issuable shares; blocker provisions limit ownership above 4.99%.

The Schedule 13G discloses that each reporting person beneficially owns 557,179 shares representing 4.99% of outstanding common stock as of September 24, 2025, driven by exercisable warrants tied to a Securities Purchase Agreement. The disclosure clarifies excluded shares and potential aggregate holdings absent blocker provisions, which would increase reported holdings materially. For valuation or dilution analysis, note the multiple warrant tranches and the contingent nature of exercisable shares; the filing does not provide transaction pricing or economic terms of the SPA.

Corporate Governance Expert

TL;DR: This is a standard passive ownership disclosure with explicit blocker provisions and a certification of non-control intent.

The reporting parties filed a joint Schedule 13G, indicating passive intent and certifying the securities were not acquired to change control. The inclusion of blocker provisions in warrants is important governance detail: it limits voting/dispositive power escalation and preserves the reporting persons' status below control thresholds. The filing includes a joint filing agreement as an exhibit, confirming coordinated reporting but not necessarily coordinated action to influence issuer control.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

BioCardia, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

09060U606

(CUSIP Number)

09/18/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 09060U606

1

Names of Reporting Persons

Mitchell P. Kopin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 557,179.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 557,179.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

557,179.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 09060U606

1

Names of Reporting Persons

Daniel B. Asher

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 557,179.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 557,179.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

557,179.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 09060U606

1

Names of Reporting Persons

INTRACOASTAL CAPITAL, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 557,179.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 557,179.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

557,179.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BioCardia, Inc.
(b)	Address of issuer's principal executive offices: 320 Soquel Way, Sunnyvale, California 94085
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)	Citizenship: Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 09060U606
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on September 18, 2025 (the "SPA") (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on September 19, 2025), each of the Reporting Persons may have been deemed to have beneficial ownership of 600,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock represent beneficial ownership of approximately 9.4% of the Common Stock, based on (1) 5,808,734 shares of Common Stock outstanding as of August 31, 2025, as reported by the Issuer and (2) 600,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes (I) 600,000 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 1") because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock and (II) 263,677 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,463,677 shares of Common Stock. (ii) As of the close of business on September 24, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 557,179 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, and all such shares of Common Stock represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 5,808,734 shares of Common Stock outstanding as of August 31, 2025, as reported by the Issuer, plus (2) 4,800,000 shares of Common Stock issued at the closing of the transaction contemplated by the SPA and (3) 557,179 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 42,821 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock and (II) 263,677 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 863,677 shares of Common Stock.
(b)	Percent of class: 4.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 557,179
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 557,179
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mitchell P. Kopin

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin
Date:	09/24/2025

Daniel B. Asher

Signature:	/s/ Daniel B. Asher
Name/Title:	Daniel B. Asher
Date:	09/24/2025

INTRACOASTAL CAPITAL, LLC

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin, Manager
Date:	09/24/2025

Exhibit Information

Exhibit 1 - Joint Filing Agreement

FAQ

How many BioCardia (BCDA) shares do the reporting persons beneficially own?

Each reporting person is reported as beneficially owning 557,179 shares, representing 4.99% of the class as of September 24, 2025.

What limits prevent the reporting persons from owning more than 4.99%?

Intracoastal Warrant 1 and Intracoastal Warrant 2 contain blocker provisions that bar exercise to the extent such exercise would cause beneficial ownership to exceed 4.99%.

Were these securities acquired to influence control of BioCardia?

No. The filers certified that, to the best of their knowledge and belief, the securities were not acquired to change or influence control of the issuer.

Who filed this Schedule 13G for BCDA?

This Schedule 13G was filed on behalf of Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital, LLC.

Does the filing disclose the economic terms of the Securities Purchase Agreement?

No. The Schedule 13G references the SPA and issuances but does not disclose pricing or other economic terms